These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12770610)

  • 1. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients.
    Grundman M; Capparelli E; Kim HT; Morris JC; Farlow M; Rubin EH; Heidebrink J; Hake A; Ho G; Schultz AN; Schafer K; Houston W; Thomas R; Thal LJ;
    Life Sci; 2003 Jun; 73(5):539-53. PubMed ID: 12770610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of AIT-082 in healthy elderly volunteers.
    Grundman M; Farlow M; Peavy G; Kim HT; Capparelli E; Schultz AN; Salmon DP; Ferris SH; Mobs R; Thomas RG; Schafer K; Campbell K; Hake AM; Schoos B; Thal LJ;
    J Mol Neurosci; 2002 Jun; 18(3):283-93. PubMed ID: 12059047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIT-082 NeoTherapeutics Inc.
    Geerts H
    IDrugs; 1998 Oct; 1(6):694-9. PubMed ID: 18465624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study.
    Olde Rikkert MG; Verhey FR; Blesa R; von Arnim CA; Bongers A; Harrison J; Sijben J; Scarpini E; Vandewoude MF; Vellas B; Witkamp R; Kamphuis PJ; Scheltens P
    J Alzheimers Dis; 2015; 44(2):471-80. PubMed ID: 25322923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metrifonate for Alzheimer's disease.
    López-Arrieta JM; Schneider L
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
    Ott BR; Blake LM; Kagan E; Resnick M;
    J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive effects of soy lecithin-derived phosphatidylserine plus phosphatidic acid on memory, cognition, daily functioning, and mood in elderly patients with Alzheimer's disease and dementia.
    Moré MI; Freitas U; Rutenberg D
    Adv Ther; 2014 Dec; 31(12):1247-62. PubMed ID: 25414047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
    Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
    Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial.
    Hannestad J; Duclos T; Chao W; Koborsi K; Klutzaritz V; Beck B; Patel AK; Scott J; Thein SG; Cummings JL; Kay G; Braithwaite S; Nikolich K
    J Alzheimers Dis; 2021; 81(4):1649-1662. PubMed ID: 33967047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease.
    Lu M; Brashear HR
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):326-335. PubMed ID: 29920980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.
    Patat A; Parks V; Raje S; Plotka A; Chassard D; Le Coz F
    Br J Clin Pharmacol; 2009 Mar; 67(3):299-308. PubMed ID: 19523013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
    Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.